376 related articles for article (PubMed ID: 26184483)
1. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
Martinez-Balibrea E; Martínez-Cardús A; Ginés A; Ruiz de Porras V; Moutinho C; Layos L; Manzano JL; Bugés C; Bystrup S; Esteller M; Abad A
Mol Cancer Ther; 2015 Aug; 14(8):1767-76. PubMed ID: 26184483
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.
Manic S; Gatti L; Carenini N; Fumagalli G; Zunino F; Perego P
Curr Cancer Drug Targets; 2003 Feb; 3(1):21-9. PubMed ID: 12570658
[TBL] [Abstract][Full Text] [Related]
5. Cellular and molecular pharmacology of oxaliplatin.
Raymond E; Faivre S; Chaney S; Woynarowski J; Cvitkovic E
Mol Cancer Ther; 2002 Jan; 1(3):227-35. PubMed ID: 12467217
[TBL] [Abstract][Full Text] [Related]
6. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
7. Platinum resistance: the role of DNA repair pathways.
Martin LP; Hamilton TC; Schilder RJ
Clin Cancer Res; 2008 Mar; 14(5):1291-5. PubMed ID: 18316546
[TBL] [Abstract][Full Text] [Related]
8. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.
Brabec V; Kasparkova J
Drug Resist Updat; 2005 Jun; 8(3):131-46. PubMed ID: 15894512
[TBL] [Abstract][Full Text] [Related]
9. Ongoing and unsaid on oxaliplatin: the hope.
Cvitkovic E
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):8-11. PubMed ID: 9647613
[TBL] [Abstract][Full Text] [Related]
10. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.
Chen CC; Chen LT; Tsou TC; Pan WY; Kuo CC; Liu JF; Yeh SC; Tsai FY; Hsieh HP; Chang JY
Br J Cancer; 2007 Aug; 97(3):334-44. PubMed ID: 17609664
[TBL] [Abstract][Full Text] [Related]
11. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
12. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
13. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
14. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
[TBL] [Abstract][Full Text] [Related]
15. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
16. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
18. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular aspects of drugs of the future: oxaliplatin.
Di Francesco AM; Ruggiero A; Riccardi R
Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N
Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
